Biotech Values

[DewDiligence]

Sanford Bernstein has a dubious track record on these kinds of “insightful” observations about MNTA. For instance, Bernstein issued a report in January, which was picked up by Reuters (sound familiar?), asserting that FDA approval of NVS/MNTA’s Lovenox was imminent because NVS was “setting prices and soliciting pre-orders” for the generic product: #msg-45811783.

I posted in #msg-45807880 that Bernstein’s January report was BS, and it turns out it was. The bogus Bernstein report in January caused MNTA’s share price to run up substantially, which probably enabled a Bernstein client (or the firm itself) to cash out at a better price.